756503-69-2

Basic information

• Product Name: 5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine
• Synonyms: 5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine
• CAS NO: 756503-69-2
• Molecular Formula: C₁₃H₁₀BrCl₂FN₂O
• Molecular Weight: 380.0397032
• Mol File: 756503-69-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 423.4°C at 760 mmHg
• Flash Point: 209.9°C
• Appearance: /
• Density: 1.643g/cm³
• Vapor Pressure: 2.24E-07mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(756503-69-2)
• EPA Substance Registry System: 5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(756503-69-2)

Safety Data

• Hazardous Substances Data: 756503-69-2(Hazardous Substances Data)

Usage

General Description

5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine is a chemical compound with a molecular formula of C14H10BrCl2F2N3O and a molecular weight of 409.05 g/mol. It is a pyridine derivative that contains a bromo group, a fluoro group, and two chloro groups on its phenyl ring. 5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine is commonly used in pharmaceutical research and drug development as it has potential biological activities. Its structure suggests that it may have applications in the treatment of various ailments. The compound's unique chemical properties make it an interesting target for further study and potential development.

InChI:InChI=1/C13H10BrCl2FN2O/c1-6(11-8(15)2-3-9(17)12(11)16)20-10-4-7(14)5-19-13(10)18/h2-6H,1H3,(H2,18,19)

Upstream product

• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 1331786-28-7 2-(1-bromoethyl)-1,3-dichloro-4-fluorobenzene 
• 39903-01-0 2-amino-3-hydroxy-5-bromopyridine 
• 15128-82-2 3-hydroxy-2-nitropyridine 
• 691872-15-8 5-bromo-3-hydroxy-2-nitropyridine 
• 74115-13-2 5-bromopyridine-3-ol 
• 756521-08-1 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 756520-67-9 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 

Downstream Products

• 756520-48-6 5-iodo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1023327-92-5 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2-methoxypyrimidin-5-yl)-pyridin-2-amine 
• 1023327-97-0 cyclopentyl 5-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)-ethoxy)pyridin-3-yl)-phenoxy)-N-tert-butoxycarbonyl-L-norvalinate 
• 756508-98-2 6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-nicotinonitrile 
• 877399-36-5 tert-butyl 3-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate 
• 1331786-34-5 (±)-bis(Boc)-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine 
• 877399-08-1 (±)-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 
• 877400-66-3 (+/-)-PF023401066 
• 877401-42-8 tert-butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1331786-33-4 (±)-bis(Boc)-5-bromo-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)pyridin-2-amine 
• 1421270-71-4 (±)-tert-butyl 6-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate 
• 1421270-66-7 C₂₂H₂₂Cl₂FN₅O*CH₂O₂ 
• 1428476-87-2 tert-butyl 4-(4-(6-acetamido-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1428476-70-3 N-(3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-yl)acetamide 

Relevant articles and documents

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

Janus Kinase 2 (JAK2) is a kind of intracellular non-receptor protein tyrosine kinase and has been certified as an important target for the treatment of myeloproliferative neoplasms and rheumatoid arthritis. However, the low selectivity and potential safety issues restrict the clinical applications of JAK2 inhibitors. Here we found that crizotinib showed good inhibitory activity against JAK2 by enzymatic assays (IC50 = 27 nM). Then we carried out structure-based drug design and synthesized a series of compounds with an aminopyridine scaffold. Finally, compound 12k and 12l were identified as the promising inhibitors of JAK2, which exhibited high inhibitory activity (IC50 = 6 nM and 3 nM, respectively) and selectivity for JAK2 over JAK1 and JAK3, and showed potent antiproliferative activities toward HEL human erythroleukemia cells. Moreover, 12k suppressed symptoms of the collagen-induced arthritis (CIA) model in rats.

SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR

Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, a preparation method and a pharmaceutical composition thereof Also disclosed are uses of the compounds and the pharmaceutical compositions thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.

AMINO HETEROARYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R1 and R3 are defined in the Description in details. The aminoheteroaryl compounds of t